Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The EU HTA Regulation: How It Threatens Device Launches And Where The Solutions Lie

Executive Summary

Medtech needs to closely monitor how the newly adopted EU HTA Regulation is rolled out and actively seek to influence its impact to avoid major obstacles ahead. MedTech Europe’s Oliver Bisazza explains why further shaping of this new text is so critical.

You may also be interested in...



What Does The EU Regulation On HTA Mean For Medtech And When Will It Apply?

Several updates have come in recent weeks on the European Commission’s planned new Regulation on HTA, including a list of stakeholder members and updated rolling timeline. Medtech Insight explains how and when this legislation will affect the medtech sector.

French Medtech Reimbursement - How Added Value And Clinical Benefit Sway Decisions

In France, many medical devices require value assessments prior to securing market access, a process that manufacturers may find complex. Hubert Galmiche, head of medical device assessment at the French National Authority for Health (HAS) explains what the outcomes of these appraisals mean for companies.

MedTech Forum 2022: Bernasconi Mulls HTA Proposal, Speaks On New Device And Diagnostic Regs

The Medical Device and IVD Regulations are much needed, although solutions must be found quickly to address major problems created on the way. But the HTA Regulation works against the sector, MedTech Europe’s Serge Bernasconi said in a recent interview.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel